Curing HCV with Direct-Acting Antiviral (DAA) Treatment: Adherence and Rapid Onset of HCV-RNA Undetectability after 4 Weeks of Treatment with Sofosbuvir/Velpatasvir

Conference Reports for NATAP

The International Liver Congress™
EASL - European Association for the
Study of the Liver
June 22-26 2022


Curing HCV with Direct-Acting Antiviral (DAA) Treatment: Adherence and Rapid Onset of HCV-RNA Undetectability after 4 Weeks of Treatment with Sofosbuvir/Velpatasvir

	AASLD 2022 Nov 4-8